InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year

Reports Q revenue EUR 165,789 vs EUR 63, 089 last year. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx (IFRX), commented: “2024 was a highly productive year for InflaRx, with the company achieving all major development and regulatory goals across its pipeline programs and making meaningful progress in addressing critical medical needs in inflammatory diseases.” He continued: “We look forward to a catalyst-rich year in 2025 as we continue to advance our pipeline, including reaching the interim analysis for the Phase 3 trial with vilobelimab in pyoderma gangrenosum and reporting top-line Phase 2a data in chronic spontaneous urticaria and hidradenitis suppurativa with INF904, our oral C5aR inhibitor with best-in-class potential.”